Veltrop-Duits Louise A, Heemskerk Bianca, Sombroek Claudia C, van Vreeswijk Tamara, Gubbels Sophie, Toes René E M, Melief Cornelis J M, Franken Kees L M C, Havenga Menzo, van Tol Maarten J D, Schilham Marco W
Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Eur J Immunol. 2006 Sep;36(9):2410-23. doi: 10.1002/eji.200535786.
The immune response against human adenovirus (HAdV) has gained interest because of the application of HAdV-based vectors in gene therapy and the high incidence of infections in pediatric recipients of allogeneic stem cell grafts. Because antiviral medication is frequently ineffective, the option of adoptive transfer of HAdV-specific donor-derived T cells in these immunocompromised patients is investigated. To generate good manufacturing practice-compatible reagents, a panel of 63 long, overlapping, peptides of the hexon protein was screened for recognition by T cells. Five conserved peptides of 30 amino acids were identified that were recognized by the majority of adult donors. CD4+ T cells from long-term cultures of PBMC, stimulated with this set of five peptides, recognized cells infected with HAdV serotypes belonging to different species. These data demonstrate that adult human T cells preferentially recognize conserved sequences of amino acid residues from a structural protein of HAdV. In the context of gene therapy, this observation may limit the beneficial effect of switching to HAdV-based vectors derived from less common serotypes of HAdV in an attempt to circumvent pre-existing immunity. However, this cross-reactivity benefits the application of HAdV-specific T cells for adoptive immunotherapy in immunocompromised transplant recipients.
由于基于人腺病毒(HAdV)的载体在基因治疗中的应用以及同种异体干细胞移植儿科受者中感染的高发生率,针对HAdV的免疫反应受到了关注。由于抗病毒药物常常无效,因此研究了在这些免疫受损患者中过继转移HAdV特异性供体来源T细胞的选择。为了生成符合药品生产质量管理规范(GMP)的试剂,对一组63个六邻体蛋白的长重叠肽进行了筛选,以检测T细胞的识别情况。鉴定出5个30个氨基酸的保守肽,大多数成年供体均可识别。用这一组5个肽刺激外周血单个核细胞(PBMC)长期培养物中的CD4 + T细胞,可识别感染不同种HAdV血清型的细胞。这些数据表明,成年人类T细胞优先识别HAdV结构蛋白氨基酸残基的保守序列。在基因治疗的背景下,这一观察结果可能会限制转而使用源自HAdV较不常见血清型的基于HAdV的载体以规避预先存在的免疫的有益效果。然而,这种交叉反应性有利于HAdV特异性T细胞在免疫受损移植受者中的过继免疫治疗应用。